Updated April 21, 2022
Notice ID: 75D301-22-R-72191
The purpose of this requirement is to estimate the value to the healthcare system and society of clinical care-based interventions that improve performance measures across the LTBI care cascade. The interventions are funded through contracts with four different TBESC-III sites, which focus on increasing identification of persons at high risk for LTBI, increasing testing with recommended diagnostics, and ensuring treatment of LTBI among non-U.S.– born persons in U.S. primary care settings.
The contractor shall hold primary responsibility for ensuring the completion of the TBESC-III cost-effectiveness analysis. The contractor shall review the effectiveness and cost data submitted to CDC by TBESC-III sites, and design and carryout the cost-effectiveness analyses in collaboration with the TBESC-III sites, listed below: • Denver Health and Hospital Authority, • Kaiser Foundation Research Institute, • Public Health – Seattle & King County, and • The Regents of the University of California, San Francisco. This requirement will also involve collaboration with CDC’s Division of TB Elimination (DTE); Surveillance, Epidemiology, and Outbreak Investigations Branch (SEOIB) staff. DTE/SEOIB leads the TBESC. Collaboration with other CDC staff (e.g., economists, evaluators) may also be required.
Task 1: Develop cost-effectiveness analysis plan The contractor shall: 1.1 Frame the cost-effectiveness analysis to include: a. Time frame of the intervention. b. Perspectives to be analyzed, including at least a healthcare system perspective and a societal perspective. If the outcomes at the TBESC-III site are expected to differ by clinic within the site, the perspective of the primary care clinic might be also used. c. Analytic horizon, i.e., the period of costs and effectiveness that will be analyzed. d. 3% annual discounting for all future costs and outcomes, related to the intervention. 1.2 Identify data needed for cost-effectiveness analysis. 1.3 Define key assumptions. 1.4 Create or adapt a cost-effectiveness model. Task 2: Conduct monthly project management calls with CDC, and consult with TBESC-III sites (as needed) The contractor shall: 2.1 Conduct a one-hour telephone call monthly with the Contracting Officer’s Representative (COR) and relevant CDC project staff to discuss and report on project management issues and provide minutes or a summary after the call that documents the discussion, decisions made, and next steps. 2.2 Provide technical assistance to TBESC-III research sites regarding data collection and elements related to the cost and cost-effectiveness analysis as directed by the COR. Task 3: Review cost data Upon receipt of baseline, start-up, and each batch of intervention cost data from CDC, the contractor shall review data for clarity, accuracy, and comprehensiveness. Task 4: Finalize/approve cost data The contractor shall communicate to the COR, CDC staff, and TBESC-III sites any issues found during their quality control/assurance process and collaborate with all parties to ensure data revisions. This shall occur through summary reports provided by the contractor to the COR, as well as one-hour telephone calls with the COR and relevant CDC project staff to review and discuss any need for clarification of the cost data or any other topic related to the cost Page 5 of 55 data provided by CDC. The contractor shall provide minutes or a summary after each call that documents the discussion, decisions made, and next steps. Task 5: Categorize baseline cost data The contractor shall categorize baseline cost data for each of the four TBESC-III sites. Baseline costs are costs of targeted testing and treatment (TTT)-related activities during the baseline period prior to the intervention. These costs will be compared with intervention costs to assess the additional cost of the intervention. Baseline costs shall include: a. Costs to the healthcare system: i. Time and value of time of staff involved in baseline TTT activities ii. Costs of medical exams, medications/treatment regimens, supplies, travel, and other related costs for baseline TTT activities (including administration). b. Costs to patients for: i. Out-of-pocket expenses ii. Non-insurance covered billed services (from claims data) iii. Travel (patient reported) iv. Travel costs (estimated by observation and via interviews) v. Day or adult care vi. Other costs related to LTBI testing or treatment vii. Lost pay and work time (lost productivity)
Posted March 25, 2022
Notice ID: 75D301-22-R-72191
“The Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) has a requirement for a contract to estimate the value to the healthcare system and society of clinical care-based interventions that improve performance measures across the LTBI care cascade. The interventions are funded through contracts with four different TBESC-III sites, which focus on increasing identification of persons at high risk for LTBI, increasing testing with recommended diagnostics, and ensuring treatment of LTBI among non-U.S.–born persons in U.S. primary care settings.”
“The contractor shall hold primary responsibility for ensuring the completion of the TBESC-III cost-effectiveness analysis. The contractor shall review the effectiveness and cost data submitted to CDC by TBESC-III sites, and design and carryout the cost-effectiveness analyses in collaboration with the TBESC-III sitesThe study requires the contractor to implement an LTBI targeted testing and treatment program at their respective institution(s) in a primary healthcare setting. The contractor shall collect and provide CDC-specified data elements, including deidentified patient-level data…”
“The CDC anticipates a Time and Materials contract with a 48-month period of performance.”
“The complete solicitation document, and reference material, if applicable, is anticipated to be available for downloading at SAM.gov on or about April 11, 2022 and proposals are anticipated to be due on or about May 10, 2022.”
